Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interpreting serum risperidone concentrations.

Joel M Boerth1, Charles F Caley, John W Goethe

  • 1Veterans Affairs San Diego Health Care, San Diego, California, USA.

Pharmacotherapy
|March 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric learning experiences in PGY1 pharmacy residency training: A 5-year analysis.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024
Same author

Addressing the Conflict Between Promoting Wellness, Perpetuating Mental Illness Stigma and Making Psychiatric Pharmacy Education Less Intense.

American journal of pharmaceutical education·2021
Same author

Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection.

Psychiatry research·2021
Same author

Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints.

Contemporary clinical trials·2019
Same author

Pharmacogenetic clinical decision support for psychiatric hospitalization: Design of the CYP-GUIDES randomized controlled trial.

Contemporary clinical trials·2019
Same author

Predictors of response to synchronized transcranial magnetic stimulation for major depressive disorder.

Depression and anxiety·2018

This study explores risperidone adherence in schizophrenia patients. A novel method estimates target concentrations to help clinicians identify noncompliance with risperidone treatment.

Area of Science:

  • Pharmacology
  • Psychiatry

Background:

  • Risperidone, an atypical antipsychotic, treats schizophrenia and psychotic disorders.
  • Therapeutic drug monitoring for atypical antipsychotics is not routine, but serum levels assess nonadherence.
  • Risperidone metabolizes to 9-hydroxyrisperidone; both form the active moiety.

Observation:

  • Dose-proportional increases are not seen for risperidone, but for 9-hydroxyrisperidone and the active moiety.
  • A patient with schizophrenia initially showed linear increases in active moiety concentrations with dosage.
  • Further dosage increases led to a downward adjustment, with concentrations 17-36% below anticipated levels.

Findings:

  • Active moiety concentrations of risperidone did not consistently increase with dosage in a patient with schizophrenia.

Related Experiment Videos

  • Serum concentrations adjusted downward, suggesting potential nonadherence or altered pharmacokinetics.
  • A method to estimate target active moiety concentrations based on dosage was developed.

    • Implications:

    • This method may assist clinicians in evaluating risperidone nonadherence.
    • Optimizing risperidone adherence can improve treatment outcomes for schizophrenia patients.
    • Further research into atypical antipsychotic pharmacokinetics and adherence monitoring is warranted.